The global cell culture market is expected to witness a CAGR of around 11.1% over the forecast period 2021-2026.
In the context of the COVID-19 government organization in various countries, research institutes and many biotechs and pharmaceutical firms are focusing on the effective and rapid technologies for the fast diagnosis of COVID-19 and to develop vaccines/new therapeutics to overcome the current situation. Cell culture could serve as a potential platform for the development of novel vaccines for the treatment of the COVID-19 coronavirus. Researchers working on related coronaviruses SARS and MERS are focusing on cell culture-based treatment approaches for the COVID 19 treatment and also conducting research in the development of vaccines based on cell cultures.
In February 2020, Belgium Based CDMO Univercells received up to EUR 50M financing from Gamma Biosciences, a new investment platform supported by leading global investment firm KKR, that is focused on next-generation bioprocessing technologies for the production of advanced biologic therapies including gene- and cell-based therapies.
In General, the market for cell culture is driven by factors such as rising demand for vaccines, artificial organs and biopharmaceuticals, and growing focus on personalized medicine. For instance, In April 2019, Seqirus, filed an Annual Strain Update with the U.S. Food and Drug Administration (FDA) in the coming weeks, including the decision to manufacture its cell-based influenza vaccine (FLUCELVAX QUADRIVALENT) for the 2019/20 season using a cell-based candidate vaccine virus (CVV) for all four influenza strains recommended by the World Health Organization (WHO). This decision makes the entire production process exclusively cell-based.
In addition, there is a growing demand for personalized medicine across major developed economies. Technological advancements have helped the researchers to come up with novel therapies that can help treat life-threatening diseases. For vaccines as well as personalized medicine, there is mandatory use of cell culture. Hence, the market for cell culture is positively impacted due to the aforementioned factors.
Key Market Trends
Drug Development Segment to Witness Rapid Growth
Cell culture is an integral part of medical research and drug discovery. The two-dimensional (2D) culture has been the preferred method for many decades, due to the ease with which cell monolayers can be induced to proliferate on planar surfaces. The cell culture industry has witnessed the evolution and currently, there has been an emergence of 3D cell culture in the market. Drug development is a time taking and costly procedure which is finished in multiple stages from target identification to lead discovery and optimization, preclinical validation and clinical trials culminating in approval for clinical use. Currently, cell-based High Throughput Screening (HTS) is being carried out on cultured cells propagated in two dimensions (2D) on plastic surfaces optimized for tissue culture. With the emergence of 3D cell culture, the process of HTS has become easier and accurate.
Furthermore, with the Coronavirus disease (COVID-19) outbreak situation, the drug development process is on peak, across the biotech industry. Several companies and research organizations are involved in developing coronavirus drugs/vaccines. For instance, Entos Pharmaceuticals, Roivant Sciences, Altimmune, Biopharma, etc. are involved in the drug development for treating the contagious coronavirus infection, which is expected to propel the segment growth.
Added to the benefits of cell culture, there is a growing drug discovery being done across the globe which is augmenting the growth of the market.
North America Dominates the Global Cell Culture Market Over the Forecast Period
North America is currently dominating the cell culture market and is expected to follow the same trend over the forecast period. This is majorly attributed to the growing demand for personalized medicine and the presence of key players in the market. Added to that, the United States government is supportive in terms of medical research as healthcare is one of the major priorities in the country. The Human Cancer Models Initiative was announced, which aimed to grow 1,000 new cell lines for scientists to study within three years. Members of the initiative included the US National Cancer Institute (NCI) in Bethesda, Maryland, Cancer Research UK, the Wellcome Trust Sanger Institute UK, and Hubrecht Organoid Technology of Utrecht in the Netherlands.
Fetal bovine serum (FBS) is the most widely used growth supplement for cell culture because it cost-effectively supports the survival and growth of many cell lines. However, the FDA has put several requirements in place for the production process due to the risk of contamination. Furthermore, in 2019, the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) released their first official policy document on the joint regulation of cell-cultured meat. With the rising focus on cell-based research, it is believed that there will be more technological advancements in the field and this will impact the United States market in a positive manner.
In addition , with the COVID 19 pandemic, still evolving with the new staints, researchers working towards to study the mechanisms underlying COVID 19. For instance, in January 20, 2020, CDC has receieved specimen collected from the first reported patient in United States and generated enough SARS-CoV-2 grown in cell culture to distribute to medical and scientific researchers. All these factors are projected to boost the market growth for cell culture in United States.
The cell culture market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Thermo Fisher Scientific, Danaher Corporation, Sartorius AG, etc. are in turn, increasing the overall competitive rivalry of the market. In October 2019, Thermo Fisher Scientific launched cell culture media, which is the first to remain stable when stored at room temperature. The product advancements and improvements in cell culture platforms by the major players are increasing the competition.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
TABLE OF CONTENTS
- 1.1 Study Deliverables
- 1.2 Study Assumptions
- 1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.2.1 Rise in the Demand for Vaccines, Biopharmaceuticals and Artificial Organs
- 4.2.2 Growing Focus on Personalized Medicine
- 4.3 Market Restraints
- 4.3.1 High Cost Associated With Cell Based Research
- 4.3.2 Lack of Infrastructure for Cell-Based Research in Emerging Economies
- 4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
- 5.1 By Product and Consumables
- 5.1.1 Product
- 184.108.40.206 Biosafety Equipment
- 220.127.116.11 Centrifuges
- 18.104.22.168 Cryostorage Equipment
- 22.214.171.124 Culture Systems/Bioreactors
- 126.96.36.199 Incubators
- 188.8.131.52 Pipetting Instruments
- 184.108.40.206 Others
- 5.1.2 Consumables
- 220.127.116.11 Media
- 18.104.22.168 Sera
- 22.214.171.124 Reagents
- 5.2 By Application
- 5.2.1 Biopharmaceuticals
- 5.2.2 Drug Development
- 5.2.3 Gene Therapy
- 5.2.4 Tissue Culture & Engineering
- 5.2.5 Vaccine Production
- 5.2.6 Others
- 5.3 Geography
- 5.3.1 North America
- 126.96.36.199 United States
- 188.8.131.52 Canada
- 184.108.40.206 Mexico
- 5.3.2 Europe
- 220.127.116.11 Germany
- 18.104.22.168 United Kingdom
- 22.214.171.124 France
- 126.96.36.199 Italy
- 188.8.131.52 Spain
- 184.108.40.206 Rest of Europe
- 5.3.3 Asia-Pacific
- 220.127.116.11 China
- 18.104.22.168 Japan
- 22.214.171.124 India
- 126.96.36.199 Australia
- 188.8.131.52 South Korea
- 184.108.40.206 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 220.127.116.11 GCC
- 18.104.22.168 South Africa
- 22.214.171.124 Rest of Middle East and Africa
- 5.3.5 South America
- 126.96.36.199 Brazil
- 188.8.131.52 Argentina
- 184.108.40.206 Rest of South America
6 COMPETITIVE LANDSCAPE
- 6.1 Company Profiles
- 6.1.1 Biospherix
- 6.1.2 CellGenix GmbH
- 6.1.3 Hi-Media Laboratories
- 6.1.4 Merck KGaA
- 6.1.5 Promocell GmbH
- 6.1.6 Sartorius AG
- 6.1.7 Thermo Fisher Scientific
- 6.1.8 Danaher Corporation
- 6.1.9 Sekisui XenoTech, LLC
- 6.1.10 ANGUS Chemical Company
- 6.1.11 Lonza Group
- 6.1.12 Agilent Technologies, Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS